Stay updated with breaking news from Epsilogen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Financing led by Novartis Venture Fund and joined by new investors 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property alongside founding investor Epidarex Capital
Epsilogen Limited Announces Nature Cites IgE Antibodies as Technology to Watch Epsilogen is the leading developer of novel IgE antibodies for the treatment of cancer LONDON, UK / ACCESSWIRE / February 16, 2021 / Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, notes that IgEs and their potential as "a great way for targeting cancer cells for killing" 1 were cited in a Technology Feature article in the leading science journal, Nature. Entitled "Seven technologies to watch in 2021" 2, the article provided views from seven leading res...